Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001398733-25-000013
Filing Date
2025-08-11
Accepted
2025-08-11 16:11:29
Documents
94
Period of Report
2025-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q aqst-20250630.htm   iXBRL 10-Q 1439232
2 EX-31.1 q22025ex311.htm EX-31.1 10715
3 EX-31.2 q22025ex312.htm EX-31.2 10926
4 EX-32.1 q22025ex321.htm EX-32.1 6291
5 EX-32.2 q22025ex322.htm EX-32.2 6352
  Complete submission text file 0001398733-25-000013.txt   8463065

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT aqst-20250630.xsd EX-101.SCH 67807
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT aqst-20250630_cal.xml EX-101.CAL 65646
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT aqst-20250630_def.xml EX-101.DEF 387515
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT aqst-20250630_lab.xml EX-101.LAB 766612
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT aqst-20250630_pre.xml EX-101.PRE 588598
96 EXTRACTED XBRL INSTANCE DOCUMENT aqst-20250630_htm.xml XML 1134169
Mailing Address 30 TECHNOLOGY DRIVE WARREN NJ 07059
Business Address 30 TECHNOLOGY DRIVE WARREN NJ 07059 908-941-1900
Aquestive Therapeutics, Inc. (Filer) CIK: 0001398733 (see all company filings)

EIN.: 208623253 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38599 | Film No.: 251202110
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)